LRMR Earnings & Financial Statements
Larimar Therapeutics, Inc.
$2.06
-$0.03(-1.67%)
27
Overall
60
Value
9
Tech
13
Quality
Market Cap
$217.12M
Volume
387.27K
52W Range
$2.61 - $6.42
Target Price
$14.40
LRMR earnings and financial statements: Larimar Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LRMR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.50M | -$90.89M | -$41.76M | -$36.53M | -$50.47M |
| EBITDA | -$167.02M | -$85.54M | -$36.64M | -$36.21M | -$50.14M |
| Net income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M |
| EPS (diluted) | $-2.27 | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $145.84M | $200.22M | $95.94M | $126.41M | $78.67M |
| Total liabilities | $67.76M | $28.41M | $14.21M | $15.50M | $14.25M |
| Shareholders’ equity | $78.08M | $171.81M | $81.72M | $110.90M | $64.41M |
| Cash and equivalents | $85.41M | $33.22M | $26.75M | $26.82M | $70.10M |
| Long-term debt | $2.96M | $4.06M | $4.71M | $4.80M | $5.41M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$113.20M | -$70.80M | -$33.50M | -$27.57M | -$42.10M |
| Capital expenditure | -$91.0K | -$515.0K | -$164.0K | -$100.0K | -$333.0K |
| Free cash flow | -$113.29M | -$71.31M | -$33.66M | -$27.67M | -$42.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LRMR | $2.06 | -1.7% | 387.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Larimar Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW